Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | SCN4A | P35499 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.41 |
| ▸ | TYR | P14679 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10262511 | 0.86 | ALDH1A1 (0.47) | PSMB5ALDH1A1MEN1KMT2ACYP1A2 | |
| SCHEMBL10262257 | 0.86 | CYP1A2 (0.53) | NPC1RAB9ASCN4ASMN1; SMN2PSMB5 | |
| SCHEMBL11322091 | 0.86 | OGA (0.40) | NPC1RAB9ASCN4ASMN1; SMN2PSMB5 | |
| SCHEMBL19514112 | 0.85 | NPC1 (0.40) | NPC1RAB9ASCN4ASMN1; SMN2PSMB5 | |
| SCHEMBL12938113 | 0.85 | UGT2B7 (0.39) | NPC1RAB9ASCN4ASMN1; SMN2PSMB5 | |
| SCHEMBL7727165 | 0.85 | NPC1 (0.47) | NPC1RAB9ASCN4ASMN1; SMN2PSMB5 | |
| SCHEMBL15686689 | 0.85 | PDGFRB (0.40) | KDM4ECYP1A2MET | |
| SCHEMBL20009337 | 0.85 | HRH4 (0.38) | NPC1RAB9ASMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL19514095 | 0.85 | NPC1 (0.40) | NPC1RAB9ASCN4ASMN1; SMN2PSMB5 | |
| SCHEMBL19514121 | 0.82 | ALDH1A1 (0.51) | ALDH1A1PTGS1CYP1A2F2GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11738013-B2 | Methods for treating hepatitis B virus infections using NS5A, NS5B or NS3 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230159573-A1 | SMALL MOLECULE STAT PROTEIN DEGRADERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-25 | — | — | US | disclosed |
| US-20230133504-A1 | METHOD OF TREATING GRAFT-VERSUS-HOST DISEASE | REGENTS OF THE UNIVERSITY OF MICHIGAN | 2023-05-04 | — | — | US | disclosed |
| WO-2021160132-A1 | HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海美悦生物科技发展有限公司 | 2021-08-19 | — | — | WO | disclosed |
| WO-2020198435-A1 | SMALL MOLECULE DEGRADERS OF STAT3 | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-10-01 | — | — | WO | disclosed |
| US-10611765-B2 | Pyrrolopyrimidine derivatives as Mps1/TTK kinase inhibitors | OHIO STATE INNOVATION FOUNDATION | 2020-04-07 | — | — | US | disclosed |
| US-20190106422-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS MPS1/TTK KINASE INHIBITORS | OHIO STATE INNOVATION FOUNDATION | 2019-04-11 | — | — | US | disclosed |
| US-20180155341-A1 | Antibacterial Compounds | JANSSEN SCIENCES IRELAND UC (IE) | 2018-06-07 | — | — | US | disclosed |
| US-20180155341-A1 | Antibacterial Compounds | JANSSEN SCIENCES IRELAND UC (IE) | 2018-06-07 | — | — | US | disclosed |
| US-9873716-B2 | Macrocyclic inhibitors of flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20140274884-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140030221-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | CYPRALIS LIMITED (GB) | 2014-01-30 | — | — | US | disclosed |
| US-20140023616-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | SELCIA LIMITED (GB) | 2014-01-23 | — | — | US | disclosed |
| US-20140017198-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2014-01-16 | — | — | US | disclosed |
| US-8513184-B2 | Macrocyclic inhibitors of flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20130022573-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | SELCIA LIMITED (GB) | 2013-01-24 | — | — | US | disclosed |
| US-20130022573-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | SELCIA LIMITED (GB) | 2013-01-24 | — | — | US | disclosed |
| US-8110687-B2 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-20100190766-A1 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140030221-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, ZC3HAV1, HCCS | NPC1 80/4885RAB9A 2218/4885SCN4A 3222/4885 |
| US-20190106422-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS MPS1/TTK KINASE INHIBITORS | TTBK1, TTK, TTBK2 | NPC1 903/4885RAB9A 2100/4885SCN4A 3431/4885 |
| US-20100190766-A1 | ANTIBACTERIAL AGENTS | MRPL21, SI, ABCB11 | NPC1 299/4885RAB9A 509/4885SCN4A 3421/4885 |
| US-11738013-B2 | Methods for treating hepatitis B virus infections using NS5A, NS5B or NS3 inhibitors | HAVCR2, EIF2AK2, HSP90B1 | NPC1 151/4885RAB9A 1003/4885SCN4A 2793/4885 |
| US-10611765-B2 | Pyrrolopyrimidine derivatives as Mps1/TTK kinase inhibitors | TTBK1, TTK, TTBK2 | NPC1 903/4885RAB9A 2100/4885SCN4A 3431/4885 |
| US-20180155341-A1 | Antibacterial Compounds | FDPS, SQOR, NDUFS3 | NPC1 1147/4885RAB9A 3094/4885SCN4A 4715/4885 |
| US-20230133504-A1 | METHOD OF TREATING GRAFT-VERSUS-HOST DISEASE | HLA-DRB1, CD74, HLA-C | NPC1 952/4885RAB9A 3054/4885SCN4A 4739/4885 |
| US-20140023616-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, ZC3HAV1, CYP2F1 | NPC1 84/4885RAB9A 2195/4885SCN4A 3140/4885 |
| US-20140274884-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, LIPC | NPC1 8/4885RAB9A 1069/4885SCN4A 3981/4885 |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MAP3K20, MAP3K1, MAP3K5 | NPC1 1541/4885RAB9A 2160/4885SCN4A 3338/4885 |
| US-20230159573-A1 | SMALL MOLECULE STAT PROTEIN DEGRADERS | STAT1, STAT3, STAT5A | NPC1 4078/4885RAB9A 1035/4885SCN4A 2913/4885 |
| US-20140017198-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, GOT1 | NPC1 20/4885RAB9A 1219/4885SCN4A 4195/4885 |
| US-20130022573-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, ZC3HAV1, CYP2F1 | NPC1 84/4885RAB9A 2195/4885SCN4A 3140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.